Cencora, Inc.

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cencora, Inc. and other ETFs, options, and stocks.

About COR

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. 

CEO
Robert P. Mauch
CEORobert P. Mauch
Employees
51,000
Employees51,000
Headquarters
Conshohocken, Pennsylvania
HeadquartersConshohocken, Pennsylvania
Founded
1947
Founded1947
Employees
51,000
Employees51,000

COR Key Statistics

Market cap
61.69B
Market cap61.69B
Price-Earnings ratio
23.66
Price-Earnings ratio23.66
Dividend yield
0.76%
Dividend yield0.76%
Average volume
1.36M
Average volume1.36M
High today
$320.25
High today$320.25
Low today
$320.25
Low today$320.25
Open price
$318.03
Open price$318.03
Volume
183.00
Volume183.00
52 Week high
$377.54
52 Week high$377.54
52 Week low
$244.82
52 Week low$244.82

Stock Snapshot

As of today, Cencora, Inc.(COR) shares are valued at $320.25. The company's market cap stands at 61.69B, with a P/E ratio of 23.66 and a dividend yield of 0.76%.

As of 2026-08-06, Cencora, Inc.(COR) stock has fluctuated between $320.25 and $320.25. The current price stands at $320.25, placing the stock 0.0% above today's low and 0.0% off the high.

Cencora, Inc.(COR) shares are trading with a volume of 183, against a daily average of 1.36M.

During the past year, Cencora, Inc.(COR) stock moved between $244.82 at its lowest and $377.54 at its peak.

During the past year, Cencora, Inc.(COR) stock moved between $244.82 at its lowest and $377.54 at its peak.

COR News

TipRanks 1h
Cencora price target raised to $370 from $355 at Citi

Citi raised the firm’s price target on Cencora (COR) to $370 from $355 and keeps a Buy rating on the shares. The firm views the company’s earnings report as sol...

Simply Wall St 10h
Cencora Stock Climbs As Margin Expansion Drives Profit Momentum

Cencora stock jumped 3.6% to US$317.22 after earnings, even though the headline result was all about profit pressure rather than a revenue surprise. The company...

Cencora Stock Climbs As Margin Expansion Drives Profit Momentum
TipRanks 12h
Cencora Earnings Call Highlights Specialty-Driven Profit Surge

Cencora, Inc. ((COR)) has held its Q3 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investing tools with Ti...

Analyst ratings

78%

of 18 ratings
Buy
77.8%
Hold
22.2%
Sell
0%

More COR News

Benzinga 19h
Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins

The pharmaceutical solutions organization reported sales of $84.754 billion, up 5.1% year-over-year, beating the consensus of $84.315 billion, driven by steady...

Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins
TipRanks 1d
Cencora Raises 2026 EPS Outlook After Strong Quarter

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Simply Wall St 4d
Cencora Stock May Be 38% Undervalued As Cash Flow Holds Up

Cencora stock has delivered strong long term returns over the past five years, yet the current share price still screens as cheap relative to its intrinsic valu...

Cencora Stock May Be 38% Undervalued As Cash Flow Holds Up

People also own

Based on the portfolios of people who own COR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.